ErbB2+metastatic breast cancer treatment after progression on trastuzumab: a cost-effectiveness analysis for a developing country

Cost Effectiveness ◽

Cancer Treatment ◽

Developing Country ◽

Metastatic Breast ◽

Breast Cancer Treatment ◽

Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial

BMC Cancer ◽

10.1186/s12885-017-3774-7 ◽

2017 ◽

Vol 17 (1) ◽

Author(s):

Takeru Shiroiwa ◽

Takashi Fukuda ◽

Kojiro Shimozuma ◽

Mitsuko Mouri ◽

Yasuhiro Hagiwara ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Cancer Treatment ◽

Metastatic Breast ◽

Breast Cancer Treatment ◽

Phase Iii ◽

First Line ◽

PCN69 Cost-Effectiveness Analysis of NOVEL Therapies for HER2+ Metastatic Breast Cancer: [FAM-] Trastuzumab Deruxtecan Versus Tucatinib Trastuzumab and Capecitabine Combination

Value in Health ◽

10.1016/j.jval.2020.08.206 ◽

2020 ◽

Vol 23 ◽

pp. S433-S434

Author(s):

G. Vondeling ◽

E. Palaka ◽

C. Livings ◽

J. Naik ◽

W. Sullivan

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Metastatic Breast ◽

Novel Therapies ◽

Erratum to: Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-014-3107-3 ◽

2014 ◽

Vol 147 (2) ◽

pp. 443-443 ◽

Author(s):

Vakaramoko Diaby ◽

Georges Adunlin ◽

Simon B. Zeichner ◽

Kiran Avancha ◽

Gilberto Lopes ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Hormone Receptor ◽

Metastatic Breast ◽

Hormone Receptor Positive ◽

Cost-Effectiveness Analysis of Fulvestrant in the Treatment of Metastatic Breast Cancer in Second-Line Chemotherapy

Value in Health ◽

10.1016/j.jval.2014.08.2289 ◽

2014 ◽

Vol 17 (7) ◽

pp. A637

Author(s):

I. Krysanov ◽

V. Krysanova

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Metastatic Breast ◽

Second Line ◽

Second Line Chemotherapy ◽

Effectiveness Analysis ◽

Line Chemotherapy

First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis

Breast Cancer ◽

10.1007/s12282-019-01034-6 ◽

2019 ◽

Vol 27 (3) ◽

pp. 399-404 ◽

Author(s):

Weiting Liao ◽

Jiaxing Huang ◽

Qiuji Wu ◽

Feng Wen ◽

Nan Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Metastatic Breast ◽

First Line ◽

Hormone Receptor Positive ◽

COST-EFFECTIVENESS ANALYSIS OF OPTIMAL CONTROL STRATEGIES FOR BREAST CANCER TREATMENT WITH KETOGENIC-DIET

Far East Journal of Mathematical Sciences (FJMS) ◽

10.17654/ms109020303 ◽

2018 ◽

Vol 109 (2) ◽

pp. 303-342 ◽

Author(s):

S. I. Oke ◽

M. B. Matadi ◽

S. S. Xulu

Keyword(s):

Breast Cancer ◽

Optimal Control ◽

Cost Effectiveness ◽

Cancer Treatment ◽

Ketogenic Diet ◽

Control Strategies ◽

Breast Cancer Treatment ◽

Cost-effectiveness analysis of routine use of eribulin in patients with metastatic breast cancer in France: A retrospective analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.e11531 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e11531-e11531

Author(s):

Marie-Justine Paillard ◽

Elsa Curtit ◽

Virginie Nerich ◽

Laurent Cals ◽

Fernando Bazan ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Retrospective Analysis ◽

Metastatic Breast ◽

Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer In Spain: Management in the Later Lines of Therapy

Value in Health ◽

10.1016/j.jval.2015.03.1175 ◽

2015 ◽

Vol 18 (3) ◽

pp. A203 ◽

Author(s):

U. Majethia ◽

G. Tremblay ◽

I. Kontoudis ◽

J. DeRosendo

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Metastatic Breast ◽

Eribulin Mesylate ◽

A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan

The Breast ◽

10.1016/j.breast.2019.11.012 ◽

2020 ◽

Vol 49 ◽

pp. 141-148 ◽

Cited By ~ 2

Author(s):

Vakaramoko Diaby ◽

Hussain Alqhtani ◽

Sascha van Boemmel-Wegmann ◽

Ching-Yu Wang ◽

Askal Ayalew Ali ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Cancer Patients ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Effectiveness Analysis ◽

Her 2 ◽

Treatment Sequences

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study

ClinicoEconomics and Outcomes Research ◽

10.2147/ceor.s41850 ◽

2013 ◽

pp. 125 ◽

Cited By ~ 14

Author(s):

Carlo Lazzaro ◽

Roberto Bordonaro ◽

Francesco Cognetti ◽

Fabi ◽

Sabino De Placido ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Cancer Patients ◽

Metastatic Breast ◽

Breast Cancer Patients ◽